1. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
|
2. |
Deshpand R, Chandra M, Rauthan A. Evolving trends in lung cancer: epidemiology, diagnosis, and management. Indian J Cancer, 2022, 59(Suppl 1): S90-S105.
|
3. |
Chen PX, Liu YH, Wen YK, et al. Non-small cell lung cancer in China. Cancer Commun (Lond), 2022, 42(10): 937-970.
|
4. |
Mur P, García-Mulero S, del Valle J, et al. Role of POLE and POLD1 in familial cancer. Genet Med, 2020, 22(12): 2089-2100.
|
5. |
朱玉, 苏亚娟. DNA聚合酶ε在肿瘤中的研究进展. 实用肿瘤杂志, 2021, 36(2): 189-193.
|
6. |
Hua X, Xu HM, Yang YN, et al. DrGaP: a powerful tool for identifying driver genes and pathways in cancer sequencing studies. Am J Hum Genet, 2013, 93(3): 439-451.
|
7. |
Zhang LM, Chen JH, Yang H, et al. Multiple microarray analyses identify key genes associated with the development of non-small cell lung cancer from chronic obstructive pulmonary disease. J Cancer, 2021, 12(4): 996-1010.
|
8. |
Yoshida R, Miyashita K, Inoue M, et al. Concurrent genetic alterations in DNA polymerase proofreading and mismatch repair in human colorectal cancer. Eur J Hum Genet, 2011, 19(3): 320-325.
|
9. |
Wang F, Zhao Q, Wang YN, et al. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types. JAMA Oncol, 2019, 5(10): 1504-1506.
|
10. |
Tang H, You TT, Sun Z, et al. A comprehensive prognostic analysis of POLD1 in hepatocellular carcinoma. BMC Cancer, 2022, 22(1): 197.
|
11. |
Qin QH, Tan QX, Li JY, et al. Elevated expression of POLD1 is associated with poor prognosis in breast cancer. Oncol Lett, 2018, 16(5): 5591-5598.
|
12. |
Magrin L, Fanale D, Brando C, et al. POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes. Oncogene, 2021, 40(40): 5893-5901.
|
13. |
Nicolas E, Golemis EA, Arora S. POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologies. Gene, 2016, 590(1): 128-141.
|
14. |
Antoniali G, Marcuzzi F, Casarano E, et al. Cadmium treatment suppresses DNA polymerase δ catalytic subunit gene expression by acting on the p53 and Sp1 regulatory axis. DNA Repair (Amst), 2015, 35: 90-105.
|
15. |
Sanefuji K, Taketomi A, Iguchi T, et al. Significance of DNA polymerase delta catalytic subunit p125 induced by mutant p53 in the invasive potential of human hepatocellular carcinoma. Oncology, 2010, 79(3-4): 229-237.
|
16. |
宋勇. 晚期非小细胞肺癌的治疗. 中国呼吸与危重监护杂志, 2005, 4(3): 175-176.
|
17. |
Liu XY, Wu SC, Yang YH, et al. The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer. Biomed Pharmacother, 2017, 95: 55-61.
|
18. |
曾瑞红, 房桂珍, 魏林. CD4+ T细胞在肿瘤免疫治疗中的作用. 细胞生物学杂志, 2008, 30(1): 30-34.
|
19. |
王琰, 卢斌峰, 蒋敬庭, 等. 肿瘤浸润淋巴细胞及其亚群在肿瘤免疫中的作用. 临床检验杂志, 2018, 36(11): 854-857.
|
20. |
周越, 苑珩珩, 韩宇, 等. POLE/POLD1突变在肿瘤免疫治疗预后中的价值. 中国肿瘤, 2022, 31(3): 215-220.
|